Cover Image
Market Research Report
Product code
1020944

Endoscopy Devices for Obesity, Type II Diabetes and NASH Market by Product, Procedure, and Disease Indication : Global Opportunity Analysis and Industry Forecast, 2021-2028

Published: | Allied Market Research | 266 Pages | Delivery time: 2-3 business days

Price

Back to Top
Endoscopy Devices for Obesity, Type II Diabetes and NASH Market by Product, Procedure, and Disease Indication : Global Opportunity Analysis and Industry Forecast, 2021-2028
Published: June 25, 2021
Allied Market Research
Content info: 266 Pages
Delivery time: 2-3 business days
  • ALL
  • Description
  • Table of Contents
Description

The global endoscopy devices for obesity, type II diabetes and NASH market was valued at $2,638.99 million in 2019, and is projected to reach $3,711.43 million by 2027, registering a CAGR of 7.6% from 2021 to 2028. Endoscopy devices are the medical devices with light attached to look inside the body cavity or organ by inserting through a natural opening such as the mouth or through incisions. An endoscopy is the minimally invasive medical procedure that diagnoses, prevents, and treats complications associated with visceral organs. Endoscopic devices consist of flexible tubing that contains a series of lighted mirror lenses and optic fibers. These devices are used in the diagnosis of gastrointestinal tract, small intestine, large intestine/colon, bile duct, rectum, respiratory tract, ear, urinary tract, and female reproductive systems. The market mainly focuses on the endoscopic devices used in the endoscopic surgeries used in treating diseases such as obesity, type II diabetes, and non-alcoholic steatohepatitis.

Surge in obese population, technological advancements, rise in prevalence rate of diseases that require endoscopy devices, growth in patient preference for minimally invasive surgeries, favorable FDA approvals, and reimbursement policies in developed economies, shorter recovery time and minimal postoperative complications are the key factors that fuel the growth of the endoscopy devices for obesity, type II diabetes and NASH market. Furthermore, rise in prevalence of diabetes within the population is expected to supplement the market growth throughout the analysis period. For instance, according to the data published by National Institute of Health (NIH), in 2017, approximately 462 million individuals were affected by type II diabetes, corresponding to 6.28% of the world's population. Moreover, increase in the geriatric population vulnerable to obesity and comorbid conditions related to obesity, which necessitates the use of endoscopic procedures for diagnosis & treatment is anticipated to boost the market growth in near future. However, dearth of trained physicians & endoscopists and infections associated with the use of endoscopes are expected to hinder the growth of the market.

The global endoscopy devices for obesity, type II diabetes and NASH market is segmented into product type, procedure, disease indication, and region. By product type, the market is categorized into endoscope, mechanical endoscopic equipment, visualization & documentation systems, accessories, and other endoscopy equipment. By procedure, the market is segmented into gastric balloon, aspiration therapy, endoscopic sleeve gastroplasty, gastric injection, and lap band surgery. On the basis of disease indication, the endoscopy devices for obesity, type II diabetes and NASH market is classified into obesity, type II diabetes and nonalcoholic steatohepatitis (NASH). Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2028, which assists to identify the prevailing market opportunities.
  • An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
  • A comprehensive analysis of the factors that drive and restrain the growth of the global endoscopy devices for obesity, type II diabetes and NASH market is provided.
  • An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

  • By Product
  • Endoscope
  • Mechanical endoscopic equipment
  • Visualization and documentation systems
  • Accessories
  • Other endoscopy equipment
  • By Procedure
  • Gastric balloon
  • Aspiration therapy
  • Endoscopic sleeve gastroplasty
  • Gastric injection
  • Lap band surgery
  • By Disease indication
  • Obesity
  • Type II Diabetes
  • Nonalcoholic Steatohepatitis (NASH
  • By Region
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Apollo Endosurgery Inc.
  • Aspire Bariatrics Inc.
  • Endo Tools Therapeutics S.A
  • Fractyl Laboratories Inc.
  • GI Dynamics Inc.
  • GI Windows Inc.
  • Medtronic plc
  • Obalon Therapeutics Inc.
  • ReShape Lifesciences Inc.
  • Spatz FGIA Inc.
  • USGI Medical Inc.
Table of Contents
Product Code: A11711

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2019
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Surge in obese population
      • 3.5.1.2.Technological advancements
      • 3.5.1.3.Rise in prevalence rate of diseases that require endoscopy devices
      • 3.5.1.4.Growth in patient preference for minimally invasive surgeries
      • 3.5.1.5.Favorable FDA approvals
      • 3.5.1.6.Shorter recovery time and minimal postoperative complications
    • 3.5.2.Restraints
      • 3.5.2.1.Dearth of trained physicians and endoscopists
      • 3.5.2.2.Infections caused by few endoscopes
    • 3.5.3.Opportunities
      • 3.5.3.1.Unmet medical demands in developing countries
      • 3.5.3.2.Lucrative opportunities in emerging economies
  • 3.6.COVID-19 impact analysis
  • 3.7.Clinical data analysis
    • 3.7.1.Intragastric balloons
    • 3.7.2.AspireAssist
    • 3.7.3.Revita DMR System
    • 3.7.4.EndoBarrier
    • 3.7.5.Incision-less Anastomosis System (IAS)
    • 3.7.6.OverStitch Endoscopic Suturing System
    • 3.7.7.Endomina
    • 3.7.8.Plication Device
    • 3.7.9.Endostitch

CHAPTER 4:ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Endoscopes
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Mechanical endoscopic equipment
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Visualization and documentation systems
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country
  • 4.5.Accessories
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast
    • 4.5.3.Market analysis, by country
  • 4.6.Other endoscopy equipment
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast
    • 4.6.3.Market analysis, by country

CHAPTER 5:ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Gastric balloons
    • 5.2.1.Key market trends and opportunities
    • 5.2.2.Market size and forecast
    • 5.2.3.Market analysis, by country
  • 5.3.Aspiration therapy
    • 5.3.1.Key trends and opportunities
    • 5.3.2.Market size and forecast
    • 5.3.3.Market analysis, by country
  • 5.4.Endoscopic sleeve gastroplasty
    • 5.4.1.Key market trends and opportunities
    • 5.4.2.Market size and forecast
    • 5.4.3.Market analysis, by country
  • 5.5.Gastric injections
    • 5.5.1.Key market trends and opportunities
    • 5.5.2.Market size and forecast
    • 5.5.3.Market analysis, by country
  • 5.6.Lap band surgery
    • 5.6.1.Key market trends and opportunities
    • 5.6.2.Market size and forecast
    • 5.6.3.Market analysis, by country
  • 5.7.Others
    • 5.7.1.Key market trends and opportunities
    • 5.7.2.Market size and forecast
    • 5.7.3.Market analysis, by country

CHAPTER 6:ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Obesity
    • 6.2.1.Key market trends, growth factors and opportunities
    • 6.2.2.Market size and forecast, by region
    • 6.2.3.Market share analysis, by country
  • 6.3.Type II Diabetes
    • 6.3.1.Key market trends, growth factors and opportunities
    • 6.3.2.Market size and forecast, by region
    • 6.3.3.Market share analysis, by country
  • 6.4.Nonalcoholic Steatohepatitis (NASH)
    • 6.4.1.Key market trends, growth factors and opportunities
    • 6.4.2.Market size and forecast, by region
    • 6.4.3.Market share analysis, by country

CHAPTER 7:ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends, growth factors, and opportunities
    • 7.2.2.Market size and forecast, by country
    • 7.2.3.Market size and forecast, by product type
    • 7.2.4.Market size and forecast, by procedure
    • 7.2.5.Market size and forecast, by disease indication
      • 7.2.5.1.U.S.
      • 7.2.5.1.1.U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.2.5.1.2.U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.2.5.1.3.U.S. Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.2.5.2.Canada
      • 7.2.5.2.1.Canada Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.2.5.2.2.Canada Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.2.5.2.3.Canada Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.2.5.3.Mexico
      • 7.2.5.3.1.Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.2.5.3.2.Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.2.5.3.3.Mexico Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
  • 7.3.Europe
    • 7.3.1.Key market trends, growth factors, and opportunities
    • 7.3.2.Market size and forecast, by country
      • 7.3.2.1.Germany
      • 7.3.2.1.1.Germany Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.3.2.1.2.Germany Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.3.2.1.3.Germany Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.3.2.2.France
      • 7.3.2.2.1.France Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.3.2.2.2.France Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.3.2.2.3.France Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.3.2.3.U.K.
      • 7.3.2.3.1.U.K. Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.3.2.3.2.U.K. Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.3.2.3.3.U.K. Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.3.2.4.Italy
      • 7.3.2.4.1.Italy Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.3.2.4.2.Italy Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.3.2.4.3.Italy Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.3.2.5.Spain
      • 7.3.2.5.1.Spain Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.3.2.5.2.Spain Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.3.2.5.3.Spain Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.3.2.6.Rest of Europe
      • 7.3.2.6.1.Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.3.2.6.2.Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.3.2.6.3.Rest of Europe Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends, growth factors, and opportunities
    • 7.4.2.Market size and forecast, by country
    • 7.4.3.Market size and forecast, by product type
    • 7.4.4.Market size and forecast, by procedure
    • 7.4.5.Market size and forecast, by disease indication
      • 7.4.5.1.China
      • 7.4.5.1.1.China Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.4.5.1.2.China endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.4.5.1.3.China endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.4.5.2.Japan
      • 7.4.5.2.1.Japan Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.4.5.2.2.Japan endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.4.5.2.3.Japan endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.4.5.3.India
      • 7.4.5.3.1.India Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.4.5.3.2.India endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.4.5.3.3.India endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.4.5.4.Australia
      • 7.4.5.4.1.Australia Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.4.5.4.2.Australia Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.4.5.4.3.Australia Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.4.5.5.Rest of Asia-Pacific
      • 7.4.5.5.1.Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.4.5.5.2.Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.4.5.5.3.Rest of Asia-Pacific Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
  • 7.5.LAMEA
    • 7.5.1.Key market trends, growth factors, and opportunities
    • 7.5.2.Market size and forecast, by country
    • 7.5.3.Market size and forecast, by product type
    • 7.5.4.Market size and forecast, by procedure
    • 7.5.5.Market size and forecast, by disease indication
      • 7.5.5.1.Brazil
      • 7.5.5.1.1.Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.5.5.1.2.Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.5.5.1.3.Brazil Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.5.5.2.Saudi Arabia
      • 7.5.5.2.1.Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.5.5.2.2.Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.5.5.2.3.Saudi Arabia Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.5.5.3.South Africa
      • 7.5.5.3.1.South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.5.5.3.2.South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.5.5.3.3.South Africa Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication
      • 7.5.5.4.Rest of LAMEA
      • 7.5.5.4.1.Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by product type
      • 7.5.5.4.2.Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by procedure
      • 7.5.5.4.3.Rest of LAMEA Endoscopy devices for obesity, type II diabetes and NASH market, by disease indication

CHAPTER 8:COMPANY PROFILES

  • 8.1.APOLLO ENDOSURGERY INC.
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.ASPIRE BARIATRICS INC.
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segment
    • 8.2.4.Product portfolio
    • 8.2.5.Key strategic moves and developments
  • 8.3.ENDO TOOLS THERAPEUTICS S.A.
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segment
    • 8.3.4.Product portfolio
  • 8.4.FRACTYL LABORATORIES INC.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segment
    • 8.4.4.Product portfolio
    • 8.4.5.Key strategic moves and developments
  • 8.5.GI DYNAMICS INC.
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segment
    • 8.5.4.Product portfolio
    • 8.5.5.Key strategic moves and developments
  • 8.6.GI WINDOWS INC.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segment
    • 8.6.4.Product portfolio
    • 8.6.5.Key strategic moves and developments
  • 8.7.MEDTRONIC PLC.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
  • 8.8.OBALON THERAPEUTICS INC.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segment
    • 8.8.4.Product portfolio
    • 8.8.5.Business Performance
  • 8.9.RESHAPE LIFESCIENCES INC.
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Product portfolio
    • 8.9.4.Business performance
    • 8.9.5.Key strategic moves and developments
  • 8.10.SPATZ FGIA INC.
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segment
    • 8.10.4.Product portfolio
  • 8.11.USGI MEDICAL INC.
    • 8.11.1.Company overview
    • 8.11.2.Company snapshot
    • 8.11.3.Operating business segments
    • 8.11.4.Product portfolio
    • 8.11.5.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.OVERVIEW OF FDA STATUS FOR DEVICES USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
  • TABLE 02.CLINICAL DATA OF THE GASTRIC BALLOONS USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
  • TABLE 03.CLINICAL DATA OF THE OTHER GASTRIC BALLOONS USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
  • TABLE 04.CLINICAL PIPELINE ANALYSIS OF GASTRIC BALLOONS
  • TABLE 05.CLINICAL DATA OF THE ASPIRATION THERAPY DEVICE USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
  • TABLE 06.CLINICAL PIPELINE ANALYSIS OF ASPIRATION THERAPY DEVICE
  • TABLE 07.CLINICAL DATA OF THE REVITA DMR SYSTEM USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
  • TABLE 08.CLINICAL PIPELINE ANALYSIS OF REVITA DMR SYSTEM
  • TABLE 09.CLINICAL DATA OF ENDOBARRIER USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
  • TABLE 10.CLINICAL PIPELINE ANALYSIS OF ENDOBARRIER
  • TABLE 11.CLINICAL DATA OF INCISION-LESS ANASTOMOSIS SYSTEM (IAS) USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
  • TABLE 12.CLINICAL PIPELINE ANALYSIS OF INCISIONLESS ANASTOMOSIS
  • TABLE 13.CLINICAL DATA OF OVERSTITCH USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
  • TABLE 14.CLINICAL PIPELINE ANALYSIS OF OVERSTITCH ENDOSCOPIC SUTURING SYSTEM
  • TABLE 15.CLINICAL DATA OF ENDOMINA USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
  • TABLE 16.CLINICAL PIPELINE ANALYSIS OF ENDOMINA
  • TABLE 17.CLINICAL DATA OF PLICATION DEVICE USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
  • TABLE 18.CLINICAL PIPELINE ANALYSIS OF PLICATION DEVICE
  • TABLE 19.CLINICAL DATA OF ENDOSTITCH USED IN ENDOSCOPIC WEIGHTLOSS PROCEDURES
  • TABLE 20.CLINICAL PIPELINE ANALYSIS OF ENDOSTITCH
  • TABLE 21.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028 ($MILLION)
  • TABLE 22.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ENDOSCOPES BY REGION, 2019-2028 ($MILLION)
  • TABLE 23.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR MECHANICAL ENDOSCOPIC EQUIPMENT, BY REGION, 2019-2028 ($MILLION)
  • TABLE 24.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR VISUALIZATION AND DOCUMENTATION SYSTEM, BY REGION, 2019-2028 ($MILLION)
  • TABLE 25.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ACCESSORIES, BY REGION, 2019-2028 ($MILLION)
  • TABLE 26.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR OTHER ENDOSCOPY EQUIPMENT, BY REGION, 2019-2028 ($MILLION)
  • TABLE 27.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
  • TABLE 28.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC BALLOONS, BY REGION, 2019-2028 ($MILLION)
  • TABLE 29.ENDOSOCOPY DEVICES MARKET FOR ASPIRATION THEREAPY, BY REGION, 2019-2028 ($MILLION)
  • TABLE 30.ENDOSCOPIC DEVICES MARKET FOE ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2019-2028 ($MILLION)
  • TABLE 31.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC INJECTION, BY REGION, 2019-2028 ($MILLION)
  • TABLE 32.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET LAP BAND SURGERY, BY REGION, 2019-2028 ($MILLION)
  • TABLE 33.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET OTHERS, BY REGION, 2019-2028 ($MILLION)
  • TABLE 34.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION 2019-2028($MILLION)
  • TABLE 35.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR OBESITY, BY REGION, 2019-2028 ($MILLION)
  • TABLE 36.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR TYPE II DIABETES, BY REGION, 2019-2028 ($MILLION)
  • TABLE 37.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR NONALCOHOLIC STEATOHEPATITIS (NASH), BY REGION, 2019-2028 ($MILLION)
  • TABLE 38.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY REGION, 2019-2028 ($MILLION)
  • TABLE 39.NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
  • TABLE 40.NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)
  • TABLE 41.NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
  • TABLE 42.NORTH AMERICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)
  • TABLE 43.U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028
  • TABLE 44.U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 45.U.S. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 46.CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 47.CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 48.CANADA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 49.MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 50.MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 51.MEXICO ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 52.EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
  • TABLE 53.GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 54.GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 55.GERMANY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 56.FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 57.FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 58.FRANCE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 59.U.K. ENDOSCOPY DEVICES MARKET FOR OBESITY, TYPE II DIABETES, AN BGT5D NASH, BY PRODUCT, 2019-2028
  • TABLE 60.U.K. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 61.U.K. ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 62.ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 63.ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 64.ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 65.SPAIN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 66.SPAIN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 67.ITALY ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 68.REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 69.REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 70.REST OF EUROPE ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 71.ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
  • TABLE 72.ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)
  • TABLE 73.ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
  • TABLE 74.ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)
  • TABLE 75.CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 76.CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 77.CHINA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 78.JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 79.JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 80.JAPAN ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 81.INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 82.INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 83.INDIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 84.AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 85.AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 86.AUSTRALIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 87.REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 88.REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 89.REST OF ASIA-PACIFIC ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 90.LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY COUNTRY, 2019-2028 ($MILLION)
  • TABLE 91.LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT TYPE, 2019-2028 ($MILLION)
  • TABLE 92.LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028 ($MILLION)
  • TABLE 93.LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028 ($MILLION)
  • TABLE 94.BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 95.BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 96.BRAZIL ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 97.SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 98.SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 99.SAUDI ARABIA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 100.SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 101.SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 102.SOUTH AFRICA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 103.REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PRODUCT, 2019-2028
  • TABLE 104.REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY PROCEDURE, 2019-2028
  • TABLE 105.REST OF LAMEA ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, BY DISEASE INDICATION, 2019-2028
  • TABLE 106.APOLLO ENDOSURGERY: COMPANY SNAPSHOT
  • TABLE 107.APOLLO ENDOSURGERY: OPERATING SEGMENT
  • TABLE 108.APOLLO ENDOSURGERY: PRODUCT PORTFOLIO
  • TABLE 109.ASPIRE BARIATRICS: COMPANY SNAPSHOT
  • TABLE 110.ASPIRE BARIATRICS: OPERATING SEGMENT
  • TABLE 111.ASPIRE BARIATRICS: PRODUCT PORTFOLIO
  • TABLE 112.ASPIRE BARIATRICS: PRODUCT PORTFOLIO
  • TABLE 113.ENDO TOOLS THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 114.ENDO TOOLS THERAPEUTICS: OPERATING SEGMENT
  • TABLE 115.ENDO TOOLS THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 116.FRACTYL LABORATORIES: COMPANY SNAPSHOT
  • TABLE 117.FRACTYL LABORATORIES: OPERATING SEGMENTS
  • TABLE 118.FRACTYL LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 119.FRACTYL LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 120.GI DYNAMICS: COMPANY SNAPSHOT
  • TABLE 121.GI DYNAMICS: OPERATING SEGMENT
  • TABLE 122.GI DYNAMICS: PRODUCT PORTFOLIO
  • TABLE 123.GI DYNAMICS: PRODUCT PORTFOLIO
  • TABLE 124.GI WINDOWS: COMPANY SNAPSHOT
  • TABLE 125.GI WINDOWS: OPERATING SEGMENT
  • TABLE 126.GI WINDOWS: PRODUCT PORTFOLIO
  • TABLE 127.GI WINDOWS: PRODUCT PORTFOLIO
  • TABLE 128.MEDTRONIC: COMPANY SNAPSHOT
  • TABLE 129.MEDTRONIC: OPERATING BUSINESS SEGMENTS
  • TABLE 130.MEDTRONIC: PRODUCT PORTFOLIO
  • TABLE 131.OBALON THERAPEUTICS INC.: COMPANY SNAPSHOT
  • TABLE 132.OBALON THERAPEUTICS: OPERATING SEGMENT
  • TABLE 133.OBALON THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 134.RESHAPE LIFESCIENCES: COMPANY SNAPSHOT
  • TABLE 135.RESHAPE LIFESCIENCES INC.: PRODUCT PORTFOLIO
  • TABLE 136.RESHAPE LIFESCIENCES: PRODUCT PORTFOLIO
  • TABLE 137.SPATZ FGIA: COMPANY SNAPSHOT
  • TABLE 138.SPATZ FGIA: OPERATING SEGMENT
  • TABLE 139.SPATZ FGIA: PRODUCT PORTFOLIO
  • TABLE 140.USGI MEDICAL: COMPANY SNAPSHOT
  • TABLE 141.USGI MEDICAL: OPERATING SEGMENTS
  • TABLE 142.USGI MEDICAL: PRODUCT PORTFOLIO
  • TABLE 143.RESHAPE LIFESCIENCES: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL ENDOSCOPY DEVICES MARKET: SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2021*
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2021*
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2021*
  • FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 03.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 05.HIGH INTENSITY OF RIVALRY
  • FIGURE 06.TOP PLAYER POSITIONING, 2019
  • FIGURE 07.DRIVERS, RESTRAINTS, OPPORTUNITIES
  • FIGURE 08.COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ENDOSCOPES BY COUNTRY, 2019 & 2028 ($MILLION)
  • FIGURE 09.COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR MECHANICAL ENDOSCOPIC EQUIPMENT, BY COUNTRY, 2019 & 2028 ($MILLION)
  • FIGURE 10.COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR VISUALIZATION AND DOCUMENTATION SYSTEMS, BY COUNTRY, 2019 & 2028 ($MILLION)
  • FIGURE 11.COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR ACCESSORIES, BY COUNTRY, 2019 & 2028 ($MILLION)
  • FIGURE 12.COMPARATIVE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET, FOR OTHER ENDOSCOPY EQUIPMENT, BY COUNTRY, 2020 & 2028 ($MILLION)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC BALLOONS, BY COUNTRY, 2019 & 2028 (%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY DEVICES MARKET FOR ASPIRATION THERAPY, BY COUNTRY, 2019 & 2028 (%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPIC DEVICES MARKET FOR ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2019 & 2028 (%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR GASTRIC INJECTIONS, BY COUNTRY, 2019 & 2028 (%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPIC DEVICES MARKET FOR LAP BAND SURGERY, BY COUNTRY, 2019 & 2028 (%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ENDOSCOPIC DEVICES MARKET FOR OTHERS, BY COUNTRY, 2019 & 2028 (%)
  • FIGURE 19.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR OBESITY, BY COUNTRY, 2019 & 2028
  • FIGURE 20.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR TYPE II DIABETES, BY COUNTRY, 2019 & 2028
  • FIGURE 21.ENDOSCOPY DEVICES FOR OBESITY, TYPE II DIABETES AND NASH MARKET FOR NONALCOHOLIC STEATOHEPATITIS (NASH), BY COUNTRY, 2019 & 2028
  • FIGURE 22.REGION WISE PREVALENCE OF DIABETES, 2019, 2030 & 2045
  • FIGURE 23.SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
  • FIGURE 24.SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
  • FIGURE 25.SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
  • FIGURE 26.SURGE IN PREVALENCE OF OBESITY (BMI>30KG/M2)
  • FIGURE 27.APOLLO ENDOSURGERY: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 28.APOLLO ENDOSURGERY: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 29.APOLLO ENDOSURGERY: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 30.MEDTRONIC: NET SALES, 2018-2020 ($MILLION
  • FIGURE 31.MEDTRONIC: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 32.MEDTRONIC: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 33.OBALON THERAPEUTICS: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 34.RESHAPE LIFESCIENCES INC.: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 35.RESHAPE LIFESCIENCES: REVENUE SHARE BY REGION, 2020 (%)